title: Effect on growth of long-term treatment with intranasal triamcinolone acetonide aqueous in children with allergic rhinitis.
abstract: BACKGROUND
  Guidelines recommend treatment with intranasal corticosteroids for patients with allergic rhinitis (AR), but concerns remain about possible adverse effects.
  
  
  OBJECTIVE
  To present the 1- and 2-year growth results for children with AR treated with triamcinolone acetonide aqueous nasal spray.
  
  
  METHODS
  Thirty-nine children (aged 6.1-14.3 years at study entry) were treated with triamcinolone acetonide aqueous for 1 year, and a subset of 30 children completed a second year of treatment. The dose was physician titered to achieve control over AR symptoms. For each child, statural heights at baseline and at the 1- and 2-year (where available) visits, together with growth rates, were measured and were compared with predicted values.
  
  
  RESULTS
  There were no significant differences between measured and predicted heights at the 1- and 2-year visits. The mean (SD) measured--predicted difference was 0.3 (2.2) cm (95% confidence interval, -0.4 to 1.0 cm) at the 1-year visit and 0.5 (3.0) cm (95% confidence interval, -0.6 to 1.6 cm) at the 2-year visit. Mean differences in measured and predicted growth rates were nonsignificant at the 1- and 2-year visits.
  
  
  CONCLUSIONS
  Triamcinolone acetonide aqueous titered to control AR symptoms and given for 1 or 2 years had no significant effect on statural growth in children with AR.
authors.affiliation: Division of Allergy, Asthma, and Immunology, Department of Pediatrics, Allegheny General Hospital, Pittsburgh, Pennsylvania 15212, USA. dskoner@wpahs.org
authors.forename: David P
authors.initials: DP
authors.lastname: Skoner
authors.forename: Deborah A
authors.initials: DA
authors.lastname: Gentile
authors.forename: William J
authors.initials: WJ
authors.lastname: Doyle
mesh_terms: D000281:Administration, Intranasal; D000293:Adolescent; D001827:Body Height / Q000187:drug effects*; D002648:Child; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D006128:Growth / Q000187:drug effects*; D006801:Humans; D008297:Male; D010349:Patient Compliance; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy*; D014222:Triamcinolone Acetonide / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D005938:Glucocorticoids; D014222:Triamcinolone Acetonide